|
Lloyd John Old was one of the founders and standard-bearers of the field of cancer immunology. When Old began his career in 1958, tumor immunology was in its infancy. Today, cancer immunotherapies are emerging as a significant advance in cancer therapy.
Old’s contributions to research established many of the principles and priorities of modern tumor immunology. In earlier work, he and his colleagues introduced Bacillus Calmette-Guérin to tumor immunotherapy; discovered the first link between the major histocompatibility complex and disease; found the unexpected association between Epstein-Barr virus and nasopharyngeal carcinoma; discovered Tumor necrosis factors; defined the concept of cell-surface differentiation antigens with the discovery of TL, Lyt, and a range of other mouse antigenic systems; discovered p53, independently with two other groups; and identified the tumor immunogenicity of heat shock proteins. Old is the author or co-author of more than 800 research publications.
He held the William E. Snee Chair of Cancer Immunology at Memorial Sloan-Kettering Cancer Center, where he was director of the Ludwig Institute for Cancer Research New York Branch. He was also a trustee of the LICR Charitable Trust, and a trustee of the Virginia & D.K. Ludwig Fund for Cancer Research.6. From 1971 to 2011, he served as the founding scientific and medical director of the Cancer Research Institute, where from 2001 to 2011 he also served as director of the CRI/LICR Cancer Vaccine Collaborative, an international network dedicated to testing and optimizing therapeutic cancer vaccines. Old’s previous appointments included Chairman of the LICR Board of Directors, LICR Scientific Director, Member of the Emeritus LICR Scientific Committee, LICR Chief Executive Officer, and Associate Director of Research at MSKCC.
|
